Alemtuzumab treatment of multiple sclerosis: long-term safety and efficacy.

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

Alemtuzumab is a newly licensed treatment of active relapsing-remitting multiple sclerosis (RRMS) in Europe, which in phase II and III studies demonstrated superior efficacy over β-interferon in reducing disability progression over 2-3 years. In this observational cohort study, we sought to describe our longer-term experience of the efficacy and safety of alemtuzumab in active RRMS.

Related collections

Author and article information

Journal

Journal ID (iso-abbrev): J. Neurol. Neurosurg. Psychiatr.

Title: Journal of neurology, neurosurgery, and psychiatry

ISSN (Electronic): 1468-330X

ISSN (Print): 0022-3050

Publication date (Electronic): Feb 2015

Volume: 86

Issue: 2

Affiliations

[1 ] Department of Clinical Neurosciences, University of Cambridge, Cambridge, UK.

[2 ] Department of Neurology, Beaumont Hospital, Dublin, Ireland.

[3 ] Sydney Institute of Emerging Infectious Diseases and Biosecurity, University of Sydney, Sydney, Australia.

[4 ] Institute of Psychological Medicine and Clinical Neuroscience, Cardiff University, Cardiff, Wales, UK.

[5 ] Biostatistics Unit, Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, Australia.

Article

Publisher Item ID: jnnp-2014-307721

DOI: 10.1136/jnnp-2014-307721

PubMed ID: 24849515

SO-VID: 3e058ec3-1bc1-4b29-9fd6-9d7ad8277d32

History

Keywords: Immunology,Multiple Sclerosis

Data availability:

Keywords: Immunology, Multiple Sclerosis

Comments

Comment on this article

scite_

Cited by 87

See all cited by